Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OnKure Therapeutics, Inc.RPHM · Entity 6550 | Chief Operating Officer | December 09, 2022 | December 13, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OnKure Therapeutics, Inc.
Report date December 09, 2022 · Filed December 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2032-12-08 | Direct | 125,000 |
Reported balance
After 2022-12-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-12-09 · Grant · Acquired 125,000 · Balance 125,000 F3: The shares vest in a series of 16 successive equal quarterly installments measured from December 9, 2022 subject to Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) as of each such vesting date. |
| Common StockSEC Table I · non-derivative | Direct | 35,758 |
Reported balance
Holding disclosure · report date 2022-12-09 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 35,758 F1: Includes 4,000 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on December 8, 2022. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 13,697 |
Reported balance
Holding disclosure · report date 2022-12-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 13,697 F2: By Michael P. Cruse and Thu Anh Thuy Cruse, Trustees of The Cruse Family Revocable Living Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 4,000 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on December 8, 2022.
F2: By Michael P. Cruse and Thu Anh Thuy Cruse, Trustees of The Cruse Family Revocable Living Trust.
F3: The shares vest in a series of 16 successive equal quarterly installments measured from December 9, 2022 subject to Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) as of each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 09, 2022 Filed Dec 13, 2022 18:06 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | GrantStock option (right to buy) · Derivative | 125,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001209191-22-061031 · doc4.xml · derivative · entry 3 Cruse Michael · CIK 0001854179 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-12-08 F3 · derivative.exercise_date: The shares vest in a series of 16 successive equal quarterly installments measured from December 9, 2022 subject to Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) as of each such vesting date. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 17:12 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | PurchaseCommon Stock | 7,500 | $3.39 | $25,447.50 |
DisclosureSEC source: 0001209191-22-048534 · doc4.xml · nonDerivative · entry 1 Cruse Michael · CIK 0001854179 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,697 F1 · price: The weighted average purchase price for the transaction was $3.393. The shares were purchased at a range of prices between $3.36 and $3.48. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. F2 · ownership.nature: By Michael P. Cruse and Thu Anh Thuy Cruse, Trustees of The Cruse Family Revocable Living Trust. Read SEC document |
| August 31, 2022 Filed Aug 31, 2022 17:47 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | PurchaseCommon Stock | 3,212 | $3.21 | $10,307.31 |
DisclosureSEC source: 0001209191-22-048167 · doc4.xml · nonDerivative · entry 5 Cruse Michael · CIK 0001854179 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 6,197 F5 · price: The weighted average purchase price for the transaction was $3.209. The shares were purchased at a range of prices between $3.19 and $3.29. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. F2 · ownership.nature: By Michael P. Cruse and Thu Anh Thuy Cruse, Trustees of The Cruse Family Revocable Living Trust. Read SEC document |
| August 30, 2022 Filed Aug 31, 2022 17:47 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | PurchaseCommon Stock | 1,845 | $3.19 | $5,892.56 |
DisclosureSEC source: 0001209191-22-048167 · doc4.xml · nonDerivative · entry 4 Cruse Michael · CIK 0001854179 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 2,985 F4 · price: The weighted average purchase price for the transaction was $3.1938. The shares were purchased at a range of prices between $3.16 and $3.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. F2 · ownership.nature: By Michael P. Cruse and Thu Anh Thuy Cruse, Trustees of The Cruse Family Revocable Living Trust. Read SEC document |
| August 30, 2022 Filed Aug 31, 2022 17:47 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | PurchaseCommon Stock | 975 | $3.16 | $3,081.00 |
DisclosureSEC source: 0001209191-22-048167 · doc4.xml · nonDerivative · entry 3 Cruse Michael · CIK 0001854179 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,758 F3 · price: The weighted average purchase price for the transaction was $3.16. The shares were purchased at a range of prices between $3.11 and $3.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| August 29, 2022 Filed Aug 31, 2022 17:47 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | PurchaseCommon Stock | 1,140 | $3.24 | $3,693.60 |
DisclosureSEC source: 0001209191-22-048167 · doc4.xml · nonDerivative · entry 2 Cruse Michael · CIK 0001854179 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 1,140 F2 · ownership.nature: By Michael P. Cruse and Thu Anh Thuy Cruse, Trustees of The Cruse Family Revocable Living Trust. Read SEC document |
| August 29, 2022 Filed Aug 31, 2022 17:47 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | PurchaseCommon Stock | 83 | $3.24 | $268.92 |
DisclosureSEC source: 0001209191-22-048167 · doc4.xml · nonDerivative · entry 1 Cruse Michael · CIK 0001854179 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,783 F1 · balance_after: Includes 1,600 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on June 8, 2022. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:51 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | GrantStock option (right to buy) · Derivative | 25,000 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0001209191-22-016541 · doc4.xml · derivative · entry 1 Cruse Michael · CIK 0001854179 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-03-01 F1 · derivative.exercise_date: The shares vest in a series of 48 successive equal monthly installments measured from March 2, 2022, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) as of each such vesting date. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 16:28 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | GrantStock option (right to buy) · Derivative | 75,000 | $0.00 Strike: $6.69 | $0.00 |
DisclosureSEC source: 0001209191-21-069436 · doc4.xml · derivative · entry 2 Cruse Michael · CIK 0001854179 · Senior VP-Corporate Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-12-09 F3 · derivative.exercise_date: The shares vest in a series of 48 successive equal monthly installments measured from December 10, 2021, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) as of each such vesting date. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 16:28 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-069436 · doc4.xml · nonDerivative · entry 1 Cruse Michael · CIK 0001854179 · Senior VP-Corporate Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,100 F1 · shares: Represents a restricted stock unit award. F2 · balance_after: Includes 1,600 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on December 8, 2021. Read SEC document |
| August 25, 2021 Filed Aug 26, 2021 17:51 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | PurchaseCommon Stock | 2,500 | $7.45 | $18,616.00 |
DisclosureSEC source: 0001209191-21-053520 · doc4.xml · nonDerivative · entry 1 Cruse Michael · CIK 0001854179 · Senior VP-Corporate Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F1 · price: The weighted average purchase price for the transaction was $7.4464. The shares were purchased at a range of prices between $7.425 and $7.45. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.